Clinical experience with systemic cyclosporine A treatment in severe childhood psoriasis.
J Dermatolog Treat
; 27(4): 328-31, 2016 Aug.
Article
en En
| MEDLINE
| ID: mdl-26651208
BACKGROUND: Severe forms of psoriasis including erythrodermic or pustular psoriasis, which require a more aggressive therapeutic approach such as phototherapy or systemic therapies, are rarely seen. Systemic toxicity and long-term safety of these agents are serious concerns in children. OBJECTIVE: We report our experience on the efficacy and safety of cyclosporine A treatment in 22 patients of childhood psoriasis. METHODS: We retrospectively analyzed the records of all patients less than 18 years of age treated with systemic cyclosporine A therapy at our clinic between January 2000 and March 2009. Demographic features as well as other relevant data including previous therapies, the dosage and duration of cyclosporine A therapy, response to treatment and side effects were retrieved from the patients' records. RESULTS: A total of 22 children were treated with systemic cyclosporine A therapy. Seventeen patients were found to be excellent responders. The mean therapeutic dosage of cyclosporine A was 3.47 ± 0.62 mg/kg/day. The mean duration of cyclosporine A therapy was 5.68 ± 3.29 months. The median time to total clearance of the lesions was 4.0 weeks. CONCLUSION: We conclude that cyclosporine A therapy is equally effective and safe in pediatric psoriasis patients as in adults.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Psoriasis
/
Ciclosporina
/
Fármacos Dermatológicos
Tipo de estudio:
Observational_studies
Límite:
Adolescent
/
Child
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Dermatolog Treat
Asunto de la revista:
DERMATOLOGIA
Año:
2016
Tipo del documento:
Article
País de afiliación:
Turquía
Pais de publicación:
Reino Unido